FY2021 Financial Results

from the beginning

Become A Social Innovator

• Participants

• Forward-looking statements

• CORE PRINCIPLE and WORLD VISION

• Santen 2030

• Evolution from Vision 2020 to Santen 2030

• Executive Management Team

1. Overview

• First year of MTP2025: FY21 highlights

First year of MTP2025: FY21 highlights@

2. FY2021 Financial Results

• FY2021 Consolidated results

• FY2021 Sales bridge

FY2021 Sales bridge@

• FY2021 Operating profit bridge

3. FY2022 Outlook

• MTP2025: FY2022 positioning(1)

• MTP2025: FY2022 positioning(2)

MTP2025: FY2022 positioning(2)@

MTP2025: FY2022 positioning(2)@

MTP2025: FY2022 positioning(2)@

• FY2022 Outlook(1)

• FY2022 Outlook(2)

FY2022 Outlook(3)

• FY2022 Sales outlook bridge

• Cash flow

• Cash allocation

• Shareholder returns

4. R&D Update

• FY2021 R&D update

• Q4 FY2021 R&D update

Q4 FY2021 R&D update@

• STN1013001 (Catioprost)

• STN1013001: Top line results of P3 study in Europe and Asia

Q&A

• Q&A 1

Q&A 1@

Q&A 1@

Q&A 1@

• Q&A 2

Q&A 2@

• Q&A 3

Q&A 3@

Q&A 3@

Q&A 3@

Q&A 3@

Q&A 3@

• Q&A 4

Q&A 4@

Q&A 4@

• Q&A 5

Q&A 5@

Q&A 5@

Q&A 5@

Q&A 5@

• Q&A 6

Appendix

• Foreign exchange rate assumptions and sensitivities

• FYE March 2022 financial position

• Cash flow

• Revenue and contribution profit by region

• FY2021 revenue by region

• Financial results (IFRS)

• Financial results (core basis)

• Japan(1)

• Japan(2)

• Japan(3)

• Prescription ophthalmic market in Japan (Apr.2021‐ Mar.2022)

• Americas

• China

• Current status of global development(1)

• Current status of global development(2)

• Current status of global development(3)

• Current status of global development(4)

• FY2021 Results: Progress of main pipelines

• Plan for FY2022 and beyond: Progress in main pipelines

• STN1013001: P3 study design

@